136 related articles for article (PubMed ID: 38291566)
1. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
Hernández-Sánchez A; Villaverde-Ramiro Á; Arellano-Rodrigo E; Garrote M; Martín I; Mosquera-Orgueira A; Gómez-Casares MT; Ferrer-Marín F; Such E; Velez P; Ayala R; Angona A; de Las Heras N; Magro E; Mata-Vázquez MI; Fox ML; de Villambrosía SG; Ramírez MJ; García A; García-Gutiérrez V; Cáceres A; Durán MA; Senín A; Raya JM; González JA; Cuevas B; Xicoy B; Pérez-Encinas M; Bellosillo B; Álvarez-Larrán A; Hernández-Rivas JM; Hernández-Boluda JC;
Am J Hematol; 2024 Apr; 99(4):755-758. PubMed ID: 38291566
[TBL] [Abstract][Full Text] [Related]
2. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
3. Driver mutations in primary myelofibrosis and their implications.
Szuber N; Tefferi A
Curr Opin Hematol; 2018 Mar; 25(2):129-135. PubMed ID: 29256926
[TBL] [Abstract][Full Text] [Related]
4. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
[TBL] [Abstract][Full Text] [Related]
5. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis].
Yan X; Li B; Qin TJ; Qu SQ; Pan LJ; Wu JY; Liu D; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):15-20. PubMed ID: 33677863
[No Abstract] [Full Text] [Related]
7. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.
Tefferi A; Lasho TL; Finke C; Belachew AA; Wassie EA; Ketterling RP; Hanson CA; Pardanani A
Leukemia; 2014 Jul; 28(7):1568-70. PubMed ID: 24569778
[No Abstract] [Full Text] [Related]
8. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Loscocco GG; Rotunno G; Mannelli F; Coltro G; Gesullo F; Pancani F; Signori L; Maccari C; Esposito M; Paoli C; Vannucchi AM; Guglielmelli P
Am J Hematol; 2024 Jan; 99(1):68-78. PubMed ID: 37846894
[TBL] [Abstract][Full Text] [Related]
9. Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.
Shammo JM; Stein BL
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):552-560. PubMed ID: 27913528
[TBL] [Abstract][Full Text] [Related]
10. The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy.
Gallo D; Nicoli P; Calabrese C; Gaidano V; Petiti J; Rosso V; Signorino E; Carturan S; Bot-Sartor G; Volpe G; Frassoni F; Saglio G; Cilloni D
Cancer Med; 2016 Jul; 5(7):1650-3. PubMed ID: 27167495
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
[TBL] [Abstract][Full Text] [Related]
12. Molecular prognostication in Ph-negative MPNs in 2022.
Vannucchi AM; Guglielmelli P
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):225-234. PubMed ID: 36485130
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.
Guglielmelli P; Maccari C; Sordi B; Balliu M; Atanasio A; Mannarelli C; Capecchi G; Sestini I; Coltro G; Loscocco GG; Rotunno G; Angori E; Borri FC; Tefferi A; Vannucchi AM
Blood Cancer J; 2023 Jan; 13(1):21. PubMed ID: 36710362
[No Abstract] [Full Text] [Related]
14. Calreticulin mutations in Chinese with primary myelofibrosis.
Li B; Xu J; Wang J; Gale RP; Xu Z; Cui Y; Yang L; Xing R; Ai X; Qin T; Zhang Y; Zhang P; Xiao Z
Haematologica; 2014 Nov; 99(11):1697-700. PubMed ID: 24997152
[TBL] [Abstract][Full Text] [Related]
15. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
[TBL] [Abstract][Full Text] [Related]
16. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
17. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
Tefferi A; Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Am J Hematol; 2019 Mar; 94(3):299-305. PubMed ID: 30516848
[TBL] [Abstract][Full Text] [Related]
18. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
Zamora L; Xicoy B; Cabezón M; Fernandez C; Marcé S; Velez P; Xandri M; Gallardo D; Millá F; Feliu E; Boqué C
Leuk Lymphoma; 2015; 56(10):2973-4. PubMed ID: 25686645
[No Abstract] [Full Text] [Related]
19. Genomic characterization and prognostication applied to a Brazilian cohort of patients with myelofibrosis.
Nonino A; Campregher PV; de Souza Santos FP; Mazzeu JF; Pereira RW
Int J Hematol; 2020 Sep; 112(3):361-368. PubMed ID: 32535855
[TBL] [Abstract][Full Text] [Related]
20. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
